Xofigo (radium Ra 223) for Treatment of Patients with Castration-Resistant Prostate Cancer

Xofigo (radium Ra 223) for Treatment of Patients with Castration-Resistant Prostate Cancer

AnnualMeeting2017

2 years
612 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mark Rutstein, Vice President of Oncology Development of Bayer discusses the xofigo injection, a treatment method for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Up Next Autoplay